The global Benign Prostatic Hyperplasia Testing market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Report includes an overview of the development of the Benign Prostatic Hyperplasia Testing industry chain, the market status of Hospitals (Urinalysis, Prostate-Specific Antigen (PSA) Blood Test), Diagnostic Centers (Urinalysis, Prostate-Specific Antigen (PSA) Blood Test), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Benign Prostatic Hyperplasia Testing.
Regionally, the report analyzes the Benign Prostatic Hyperplasia Testing markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Benign Prostatic Hyperplasia Testing market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Benign Prostatic Hyperplasia Testing market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Benign Prostatic Hyperplasia Testing industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Urinalysis, Prostate-Specific Antigen (PSA) Blood Test).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Benign Prostatic Hyperplasia Testing market.
Regional Analysis: The report involves examining the Benign Prostatic Hyperplasia Testing market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Benign Prostatic Hyperplasia Testing market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Benign Prostatic Hyperplasia Testing:
Company Analysis: Report covers individual Benign Prostatic Hyperplasia Testing players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Benign Prostatic Hyperplasia Testing This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Diagnostic Centers).
Technology Analysis: Report covers specific technologies relevant to Benign Prostatic Hyperplasia Testing. It assesses the current state, advancements, and potential future developments in Benign Prostatic Hyperplasia Testing areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Benign Prostatic Hyperplasia Testing market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Benign Prostatic Hyperplasia Testing market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Market segment by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
Market segment by players, this report covers
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Benign Prostatic Hyperplasia Testing, with revenue, gross margin and global market share of Benign Prostatic Hyperplasia Testing from 2019 to 2024.
Chapter 3, the Benign Prostatic Hyperplasia Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Benign Prostatic Hyperplasia Testing market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia Testing.
Chapter 13, to describe Benign Prostatic Hyperplasia Testing research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Testing
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Benign Prostatic Hyperplasia Testing by Type
1.3.1 Overview: Global Benign Prostatic Hyperplasia Testing Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Benign Prostatic Hyperplasia Testing Consumption Value Market Share by Type in 2023
1.3.3 Urinalysis
1.3.4 Prostate-Specific Antigen (PSA) Blood Test
1.3.5 Urodynamic Test
1.3.6 Cystoscopy
1.4 Global Benign Prostatic Hyperplasia Testing Market by Application
1.4.1 Overview: Global Benign Prostatic Hyperplasia Testing Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Diagnostic Centers
1.4.4 Clinics
1.4.5 Research Institutes
1.5 Global Benign Prostatic Hyperplasia Testing Market Size & Forecast
1.6 Global Benign Prostatic Hyperplasia Testing Market Size and Forecast by Region
1.6.1 Global Benign Prostatic Hyperplasia Testing Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Benign Prostatic Hyperplasia Testing Market Size by Region, (2019-2030)
1.6.3 North America Benign Prostatic Hyperplasia Testing Market Size and Prospect (2019-2030)
1.6.4 Europe Benign Prostatic Hyperplasia Testing Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Benign Prostatic Hyperplasia Testing Market Size and Prospect (2019-2030)
1.6.6 South America Benign Prostatic Hyperplasia Testing Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Benign Prostatic Hyperplasia Testing Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 AEternaZentaris
2.1.1 AEternaZentaris Details
2.1.2 AEternaZentaris Major Business
2.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Product and Solutions
2.1.4 AEternaZentaris Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AEternaZentaris Recent Developments and Future Plans
2.2 Astellas Pharma
2.2.1 Astellas Pharma Details
2.2.2 Astellas Pharma Major Business
2.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Product and Solutions
2.2.4 Astellas Pharma Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Astellas Pharma Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Product and Solutions
2.3.4 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 IntelGenx Technologies Corp
2.4.1 IntelGenx Technologies Corp Details
2.4.2 IntelGenx Technologies Corp Major Business
2.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Product and Solutions
2.4.4 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 IntelGenx Technologies Corp Recent Developments and Future Plans
2.5 Nymox Pharmaceutical Corporation
2.5.1 Nymox Pharmaceutical Corporation Details
2.5.2 Nymox Pharmaceutical Corporation Major Business
2.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Product and Solutions
2.5.4 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Nymox Pharmaceutical Corporation Recent Developments and Future Plans
2.6 Protox Therapeutics
2.6.1 Protox Therapeutics Details
2.6.2 Protox Therapeutics Major Business
2.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Product and Solutions
2.6.4 Protox Therapeutics Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Protox Therapeutics Recent Developments and Future Plans
2.7 Quest PharmaTech
2.7.1 Quest PharmaTech Details
2.7.2 Quest PharmaTech Major Business
2.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Product and Solutions
2.7.4 Quest PharmaTech Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Quest PharmaTech Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Testing Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Benign Prostatic Hyperplasia Testing by Company Revenue
3.2.2 Top 3 Benign Prostatic Hyperplasia Testing Players Market Share in 2023
3.2.3 Top 6 Benign Prostatic Hyperplasia Testing Players Market Share in 2023
3.3 Benign Prostatic Hyperplasia Testing Market: Overall Company Footprint Analysis
3.3.1 Benign Prostatic Hyperplasia Testing Market: Region Footprint
3.3.2 Benign Prostatic Hyperplasia Testing Market: Company Product Type Footprint
3.3.3 Benign Prostatic Hyperplasia Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Testing Consumption Value and Market Share by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia Testing Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Testing Consumption Value Market Share by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia Testing Market Forecast by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia Testing Consumption Value by Type (2019-2030)
6.2 North America Benign Prostatic Hyperplasia Testing Consumption Value by Application (2019-2030)
6.3 North America Benign Prostatic Hyperplasia Testing Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Testing Consumption Value by Country (2019-2030)
6.3.2 United States Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
6.3.3 Canada Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
6.3.4 Mexico Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Testing Consumption Value by Type (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia Testing Consumption Value by Application (2019-2030)
7.3 Europe Benign Prostatic Hyperplasia Testing Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Testing Consumption Value by Country (2019-2030)
7.3.2 Germany Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
7.3.3 France Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
7.3.5 Russia Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
7.3.6 Italy Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Testing Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Testing Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Testing Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Testing Consumption Value by Region (2019-2030)
8.3.2 China Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8.3.3 Japan Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8.3.4 South Korea Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8.3.5 India Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
8.3.7 Australia Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
9 South America
9.1 South America Benign Prostatic Hyperplasia Testing Consumption Value by Type (2019-2030)
9.2 South America Benign Prostatic Hyperplasia Testing Consumption Value by Application (2019-2030)
9.3 South America Benign Prostatic Hyperplasia Testing Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Testing Consumption Value by Country (2019-2030)
9.3.2 Brazil Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
9.3.3 Argentina Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Testing Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Testing Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Testing Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Testing Consumption Value by Country (2019-2030)
10.3.2 Turkey Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
10.3.4 UAE Benign Prostatic Hyperplasia Testing Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Benign Prostatic Hyperplasia Testing Market Drivers
11.2 Benign Prostatic Hyperplasia Testing Market Restraints
11.3 Benign Prostatic Hyperplasia Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Benign Prostatic Hyperplasia Testing Industry Chain
12.2 Benign Prostatic Hyperplasia Testing Upstream Analysis
12.3 Benign Prostatic Hyperplasia Testing Midstream Analysis
12.4 Benign Prostatic Hyperplasia Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
听
听
*If Applicable.
